Hi, what are you looking for?
Teva says it will seek ‘further appellate review’
Teva is now close to the 4.6% stake in Mylan that will give it standing in the Netherlands courts.
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, are pushing Mylan to take Teva’s $40 billion take-over bid offer seriously.
In the three way takeover battle Mylan is getting nervous.
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.
Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon...
Teva Pharmaceutical Industries Ltd, an Israeli-based company, has acquired a 1.35 percent stake in Mylan through purchases on the open market, increasing pressure on...
George Soros’ Soros Fund Management, which currently manages some $30 billion in assets, announced his holdings in filings with the Securities and Exchange Commission,...
Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.